227 related articles for article (PubMed ID: 24064250)
1. Differential involvement of E2A-corepressor interactions in distinct leukemogenic pathways.
Gow CH; Guo C; Wang D; Hu Q; Zhang J
Nucleic Acids Res; 2014 Jan; 42(1):137-52. PubMed ID: 24064250
[TBL] [Abstract][Full Text] [Related]
2. Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.
Guo C; Hu Q; Yan C; Zhang J
Mol Cell Biol; 2009 May; 29(10):2644-57. PubMed ID: 19289505
[TBL] [Abstract][Full Text] [Related]
3. Critical role for a single leucine residue in leukemia induction by E2A-PBX1.
Bayly R; Murase T; Hyndman BD; Savage R; Nurmohamed S; Munro K; Casselman R; Smith SP; LeBrun DP
Mol Cell Biol; 2006 Sep; 26(17):6442-52. PubMed ID: 16914730
[TBL] [Abstract][Full Text] [Related]
4. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
[TBL] [Abstract][Full Text] [Related]
5. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of CBP/p300 recruitment in leukemia induction by E2A-PBX1.
Denis CM; Chitayat S; Plevin MJ; Wang F; Thompson P; Liu S; Spencer HL; Ikura M; LeBrun DP; Smith SP
Blood; 2012 Nov; 120(19):3968-77. PubMed ID: 22972988
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
[TBL] [Abstract][Full Text] [Related]
8. E protein silencing by the leukemogenic AML1-ETO fusion protein.
Zhang J; Kalkum M; Yamamura S; Chait BT; Roeder RG
Science; 2004 Aug; 305(5688):1286-9. PubMed ID: 15333839
[TBL] [Abstract][Full Text] [Related]
9. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.
Gardini A; Cesaroni M; Luzi L; Okumura AJ; Biggs JR; Minardi SP; Venturini E; Zhang DE; Pelicci PG; Alcalay M
PLoS Genet; 2008 Nov; 4(11):e1000275. PubMed ID: 19043539
[TBL] [Abstract][Full Text] [Related]
10. Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth.
Lee YL; Ito K; Pi WC; Lin IH; Chu CS; Malik S; Cheng IH; Chen WY; Roeder RG
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33542097
[TBL] [Abstract][Full Text] [Related]
11. The leukemia associated nuclear corepressor ETO homologue genes MTG16 and MTGR1 are regulated differently in hematopoietic cells.
Ajore R; Kumar P; Dhanda RS; Gullberg U; Olsson I
BMC Mol Biol; 2012 Mar; 13():11. PubMed ID: 22443175
[TBL] [Abstract][Full Text] [Related]
12. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
13. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
[TBL] [Abstract][Full Text] [Related]
14. E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells.
Bayly R; Chuen L; Currie RA; Hyndman BD; Casselman R; Blobel GA; LeBrun DP
J Biol Chem; 2004 Dec; 279(53):55362-71. PubMed ID: 15507449
[TBL] [Abstract][Full Text] [Related]
15. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
16. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
17. New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.
Li J; Guo C; Steinauer N; Zhang J
Front Biol (Beijing); 2016 Aug; 11(4):285-304. PubMed ID: 28261265
[TBL] [Abstract][Full Text] [Related]
18. E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.
Pi WC; Wang J; Shimada M; Lin JW; Geng H; Lee YL; Lu R; Li D; Wang GG; Roeder RG; Chen WY
Blood; 2020 Jul; 136(1):11-23. PubMed ID: 32276273
[TBL] [Abstract][Full Text] [Related]
19. The Spt-Ada-Gcn5-acetyltransferase complex interaction motif of E2a is essential for a subset of transcriptional and oncogenic properties of E2a-Pbx1.
Scheele JS; Kolanczyk M; Gantert M; Zemojtel T; Dorn A; Sykes DB; Möbest DC; Kamps MP; Räpple D
Leuk Lymphoma; 2009 May; 50(5):816-28. PubMed ID: 19399691
[TBL] [Abstract][Full Text] [Related]
20. Oligomeric self-association contributes to E2A-PBX1-mediated oncogenesis.
Lin CH; Wang Z; Duque-Afonso J; Wong SH; Demeter J; Loktev AV; Somervaille TCP; Jackson PK; Cleary ML
Sci Rep; 2019 Mar; 9(1):4915. PubMed ID: 30894657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
